Biogen to Partner with Local Biotechs C4T and Skyhawk on New Treatments

Posted by ISPE Boston
On January 7, 2019

Biogen has announced separate strategic collaborations with C4 Therapeutics (C4T) of Watertown and Skyhawk Therapeutics of Waltham to discover and develop potential new treatments for neurological conditions. C4T is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach […]

Atlas Venture Announces $250 Million Biotech Opportunity Fund

Posted by ISPE Boston
On January 7, 2019

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, has announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed fundraise. With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing Atlas portfolio companies as they progress. “We are delighted and humbled by the […]

Bristol-Myers Squibb to Acquire Celgene in Deal Worth $74 Billion

Posted by ISPE Boston
On January 7, 2019

Bristol-Myers Squibb and Celgene have announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. The Boards of Directors of both companies have approved the combination. The transaction is subject to approval by Bristol-Myers […]

Chapter Member Anniversaries: December 2018

Posted by ISPE Boston
On January 7, 2019

Please congratulate the following members celebrating milestone anniversaries in December 2018. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Michelle D. Bailey, Vertex Pharmaceuticals Judith R. Bodette, Sanofi Pasteur Biologics Jack G. Campion, P.E., The Hart Companies Carl J. Carlson, Exyte From M+W Group George A. […]

Welcome New Members!

Posted by ISPE Boston
On January 7, 2019

We would like to introduce the Members who joined ISPE in December 2018, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

Explore “Advances in Bionics and Medical Exoskeletons” on January 9th

Posted by ISPE Boston
On January 3, 2019

Attractive artificial limbs with remarkable capabilities and natural motion are replacing the rigid prosthetics and hook-and-cable systems of yesteryear. Come see how much closer new technology is bringing patients to full limb utility! Join MDG Boston on Wednesday, January 16, 2019 at Regis College for a forum on “Advances in Bionics and Medical Exoskeletons.” Who […]

Women in Pharma and MassBio Discuss Gender Diversity

Posted by Kathy Marini
On December 20, 2018

The Chapter’s Women in Pharma (WIP) group recently hosted “Bridging the Gender Diversity Gap” at the Alexion facility in the Seaport District, with audience participation one of the main drivers of the event. Featured was Liz Steele, MassBio VP of Programs and Global Affairs, who reviewed the MassBio report on gender diversity and outlined the […]

Entrada Launches with $59m in Venture Capital

Posted by ISPE Boston
On December 18, 2018

Entrada Therapeutics has raised $59 million in a Series A financing co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. Entrada was funded and incubated within 5AM’s 4:59 Initiative via a seed investment by 5AM Ventures, Roche Venture Fund and MRLV. Entrada’s proprietary intracellular biologics platform has […]

PARP Inhibitors May Offer New Treatment Options for Cancer Patients

Posted by ISPE Boston
On December 12, 2018

PARP, or poly(ADP-ribose) polymerase, is a family of proteins that helps repair damaged DNA in cells. A PARP inhibitor may prevent cancer cells from repairing their damaged DNA, which can cause cancer cells to die. This may slow the return or progress of cancer. BRCA is a gene that is linked to increased risk for […]

GSK to Acquire TESARO for $5.1 Billion

Posted by ISPE Boston
On December 12, 2018

TESARO, an oncology-focused company based in Waltham, and GlaxoSmithKline (GSK) have announced that they have entered into a definitive agreement by which GSK will acquire TESARO for an aggregate cash consideration of approximately $5.1 billion. The proposed transaction significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. TESARO […]

Page 88 of 117«‹86 878889 90 ›»